Abstract | OBJECTIVES: In this study, we sought to evaluate the association of frailty with the use of optimal guideline-directed medical therapy (GDMT) and outcomes in heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The burden of frailty in HFrEF is high, and the patterns of GDMT use according to frailty status have not been studied previously. METHODS: RESULTS: The study included 879 participants, of which 56.3% had high frailty burden (class 3 FI). A higher frailty burden was associated with a significantly higher risk of HF hospitalization or death in adjusted Cox models: high frailty vs nonfrail HR: 1.76, 95% CI: 1.20-2.58. On follow-up, participants with high frailty burden also had a significantly lower likelihood of achieving optimal GDMT: high frailty vs non-frail GDMT triple therapy use at study end: 17.7% vs 28.4%; P interaction, frailty class × time <0.001. CONCLUSIONS: Patients with HFrEF with a high burden of frailty have a significantly higher risk for adverse clinical outcomes and are less likely to be initiated and up-titrated on an optimal GDMT regimen.
|
Authors | Muhammad Shahzeb Khan, Matthew W Segar, Muhammad Shariq Usman, Sumitabh Singh, Stephen J Greene, Gregg C Fonarow, Stefan D Anker, G Michael Felker, James L Januzzi Jr, Javed Butler, Ambarish Pandey |
Journal | JACC. Heart failure
(JACC Heart Fail)
Vol. 10
Issue 4
Pg. 266-275
(04 2022)
ISSN: 2213-1787 [Electronic] United States |
PMID | 35361446
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Mineralocorticoid Receptor Antagonists
|
Topics |
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Frailty
(complications, epidemiology)
- Heart Failure
(drug therapy)
- Humans
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- Stroke Volume
|